April 26, 2013

Researchers Identify Diagenode Kit as Industry-leading Solution for Studying Global DNA Methylation

New benchmarking study published in PLOS ONE shows Diagenode’s MethylCap Kit as best overall methyl binding domain kit for MBD-seq.

Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, was recently cited for having the overall best methyl binding domain (MBD)-based kit in a benchmarking study of five commercially-available MBD-based kits designed to study genome-wide DNA methylation patterns. Aberrant DNA methylation has been associated with various diseases, including most cancers, cardiovascular disease, and Alzheimer's disease, highlighting the significance of the evaluation. Additionally, recent research shows that MBD-based sequencing is the most cost-efficient method for genome wide DNA methylation profiling.


Read more


  • Virtual ChIP workshop - January 18-19, 2022 or January 25-26, 2022
    Jan 18-Jan 26, 2022
  • Virtual DNA Methylation - January 18-19, 2022 or January 25-26, 2022
    Jan 18-Jan 26, 2022
  • Lausanne Genomics Days 2022
    Lausanne, Switzerland
    Feb 14-Feb 15, 2022
 See all events


 See all news

The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics